Associated Papers
Pharmacogenetics of First-Line Antitubercular Drugs: An Update.
Manca A et al.
Therapeutic Drug Monitoring, 2026
Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate.
Verma S et al.
Drug Discovery Today, 2026
Pharmacogenomic heterogeneity of N-acetyltransferase 2: a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review.
Thomas L et al.
Annals of Medicine, 2025
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy.
Eadon MT et al.
Clinical Pharmacology and Therapeutics, 2025
Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health.
Naderi N et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2025
Allele-specific detection of isoniazid metabolism modulating variants of N-acetyltransferase 2 enzyme and their frequencies in the Bangladeshi population.
Khan NT et al.
Gene, 2025
Colorimetric loop-mediated isothermal amplification (cLAMP) assay for the genotyping of a thrombophilia genetic risk factor, MTHFR (C677T).
Altwayan R et al.
Analytical Methods : Advancing Methods and Applications, 2025
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort.
Schiuma M et al.
International Journal of Molecular Sciences, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
The N-Acetyltransferase 2 Polymorphism and Susceptibility to Inflammatory Bowel Disease: A Case-Control Study.
Petryszyn P et al.
Pharmacology Research & Perspectives, 2025
A study of N-acetyltransferase 2 gene polymorphisms in the Indian population and its relationship with serum isoniazid concentrations in a cohort of tuberculosis patients.
Munshi R et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace, 2024
Differential distribution of NAT2 polymorphisms and NAT2 acetylator phenotypes among indigenous populations of the Brazilian Amazon.
Perini JA et al.
Pharmacogenetics and Genomics, 2024
Pharmacogenetics of therapies in rheumatoid arthritis: An update.
Babiker-Mohamed MH et al.
Best Practice & Research. Clinical Rheumatology, 2024
Variants in the N-acetyltranferase 2 gene, acetylator phenotypes and their association with tuberculosis: Findings in Peruvian patients.
Sánchez R et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2024
Determination of NAT2 Genotypes in a Cohort of Patients with Suspected TB in the State of Rio de Janeiro.
Dutra CA et al.
Pharmaceutics, 2024
Function and expression of N-acetyltransferases 1 and 2 are altered in lymphocytes in type 2 diabetes and obesity.
Paz-Rodríguez VA et al.
Biochemistry and Biophysics Reports, 2024
A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.
Verma R et al.
American Journal of Respiratory and Critical Care Medicine, 2024
N-acetyltransferase Gene Variants Involved in Pediatric Idiosyncratic Drug-Induced Liver Injury.
Alés-Palmer ML et al.
Biomedicines, 2024
Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations.
Jaramillo-Valverde L et al.
Pharmacology Research & Perspectives, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Influence of N-acetyltransferase 2 polymorphisms and clinical variables on liver function profile of tuberculosis patients.
Thomas L et al.
Expert Review of Clinical Pharmacology, 2024
Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity.
Yoon JG et al.
Experimental & Molecular Medicine, 2024
Towards pharmacogenomics-guided tuberculosis (TB) therapy: N-acetyltransferase-2 genotypes among TB-infected Kenyans of mixed ethnicity.
Njagi LN et al.
Bmc Medical Genomics, 2024
Direct Comparative Analysis of a Pharmacogenomics Panel with PacBio Hifi® Long-Read and Illumina Short-Read Sequencing.
Barthélémy D et al.
Journal of Personalized Medicine, 2023
The effect of the rs1799931 G857A (G286E) polymorphism on N-acetyltransferase 2-mediated carcinogen metabolism and genotoxicity differs with heterocyclic amine exposure.
Hein DW et al.
Archives of Toxicology, 2023
A case-control study in NAT2 gene polymorphism studies in patients diagnosed with acute myeloid leukemia.
Farasani A
Acta Biochimica Polonica, 2023
A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing.
Verma R et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Association of NAT2, GSTT1, and GSTM1 gene polymorphisms withprostate cancer risk in Bangladeshi population.
Nesa A et al.
Gene, 2023
Effect of N-acetyltransferase 2 genetic polymorphism on 4,4'-methylenebis(2-chloroaniline)-induced genotoxicity and oxidative stress.
Habil MR et al.
Archives of Toxicology, 2023
Development of Novel Mass Spectrum-Based Assay for Simultaneous Detection of 36 Variants in the 14 Pharmacogenetic Genes for the Japanese Population.
Yamamoto N et al.
Biological & Pharmaceutical Bulletin, 2023
The pharmacogenomic landscape of an Indigenous Australian population.
Samarasinghe SR et al.
Frontiers in Pharmacology, 2023
N-acetyltransferase 2 genetic polymorphisms and anti-tuberculosis-drug-induced liver injury: a correlation study.
Cheng F et al.
Frontiers in Pharmacology, 2023
Clinical Significance of NAT2 Genetic Variations in Type II Diabetes Mellitus and Lipid Regulation.
Jarrar Y et al.
Pharmacogenomics and Personalized Medicine, 2023
Targeted haplotyping in pharmacogenomics using Oxford Nanopore Technologies' adaptive sampling.
Deserranno K et al.
Frontiers in Pharmacology, 2023
Human N-acetyltransferase 2 (NAT2) gene variability in Brazilian populations from different geographical areas.
Lopes MQP et al.
Frontiers in Pharmacology, 2023
Differences in β-naphthylamine metabolism and toxicity in Chinese hamster ovary cell lines transfected with human CYP1A2 and NAT2*4, NAT2*5B or NAT2*7B N-acetyltransferase 2 haplotypes.
Habil MR et al.
Archives of Toxicology, 2022
Comparison of genetic susceptibility to lung adenocarcinoma and squamous cell carcinoma in Japanese patients using a novel panel for cancer-related drug-metabolizing enzyme genes.
Ohnami S et al.
Scientific Reports, 2022
Genetic susceptibility of bladder cancer in the Lebanese population.
Kourie HR et al.
Bmc Medical Genomics, 2022
Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).
van Rensburg R et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2022
Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy.
Khan A et al.
Global Medical Genetics, 2022
Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis.
Zyryanov SK et al.
Biomedicines, 2022
Predictive role of polymorphic variants of phase II drug metabolising enzyme in modulating toxicity in North Indian lung cancer patients undergoing chemotherapy.
Walia H et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2022
Association of NAT-2 gene polymorphisms toward lung cancer susceptibility and prognosis in North Indian patients treated with platinum-based chemotherapy.
Walia HK et al.
Pharmacogenomics, 2022
N-Acetyltransferase 2, glutathione S-transferase gene polymorphisms and susceptibility to hepatocellular carcinoma in an Algerian population.
Chorfi L et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2022
Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs.
El-Jaick KB et al.
Memorias Do Instituto Oswaldo Cruz, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.
Verma R et al.
American Journal of Respiratory and Critical Care Medicine, 2021
Allelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients.
Levano KS et al.
Molecular Genetics & Genomic Medicine, 2021